Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials

Table 1 Randomized, double-blind, active-controlled Phase III trials included in this pooled analysis

Clinical Trials.gov registration number	Background treatment	Treatment arms	Mean age (years)	Men (%)	Treatment period (weeks)	Reference
NCT04634500	Metformin alone	Enavogliflozin 0.3 mg	59.03	58.42	24	KA Han. et al. [8]
NCT04634500	Metformin alone	Dapagliflozin 10 mg	60.35	54.55	24	KA Han. et al. [8]
NCT04654390	Combination of metformin and gemigliptin	Enavogliflozin 0.3 mg	58.14	54.48	24	KS Kim, et al. [9]
NCT04654390	Combination of metformin and gemigliptin	Dapagliflozin 10 mg	59.07	50.00	24	KS Kim, et al. [9]

ISSN: 1475-2840